OncoMatch/Clinical Trials/NCT06229912

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

Is NCT06229912 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Revumenib for leukemia.

Phase 2RecruitingM.D. Anderson Cancer CenterNCT06229912Data as of May 2026

Treatment: Revumenib — To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Biomarker criteria

Required: KMT2A (MLL) partial tandem duplication

KMT2A-PTD = Normal karyotype

Required: NPM1 NPM1-MLF1 fusion

NPM1-MLF1 = t(3;5)(q25;q34)

Required: NUP98 rearrangement

NUP98r = 11p15 rearrangements

Required: SET SET-NUP214 fusion

SET-NUP214 = t(9;9)(q34;q34)

Required: RUNX1 RUNX1-EVI1 fusion

RUNX1-EVI1 = t(3;21)(q26;q22)

Required: KAT6A MYST3-CREBBP fusion

MYST3-CREBBP = t(8;16)(p11;p13)

Required: CDX2 CDX2-ETV6 fusion

CDX2-ETV6 = t(12;13)(p13;q12)

Required: PICALM CALM-AF10 fusion

CALM-AF10 = t(10;11)(p13;q14-21)

Required: MN1 MN1-ETV6 fusion

MN1-ETV6 = t(12;22)(p13;q12)

Required: UBTF UBTF-TD

UBTF-TD = Normal karyotype

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: any prior therapy — relapsed or refractory

Relapsed or refractory acute leukemia

Lab requirements

Blood counts

wbc must be below 25,000/ ul at time of enrollment

Kidney function

estimated glomerular filtration rate ≥ 60 ml/min based on local institutional practice for age-appropriate determination

Liver function

direct bilirubin < 1.5x uln unless increase is due leukemic involvement, and ast and/or alt < 3x uln unless considered due to leukemic involvement, in which case direct bilirubin or ast and/or alt < 5x uln will be considered eligible

Cardiac function

baseline ejection fraction must be > 40%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Memorial Sloan Kettering Cancer Center · New York, New York
MD Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify